Close Menu

The Worst?

TheStreet's Adam Feuerstein wants to know who you think has been the worst biotech CEO of 2011. There have been several missteps in the world of biotech this year, Feuerstein says, like "a desperate, $11 billion Hail Mary acquisition, two botched drug launches, a clueless, tin-eared investor relations strategy, and an expensive and quixotic quest to develop a product no one needs."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.